NT_1170x120_1-11-18

biosimilar naming convention

FTC comments on FDA biosimilar naming guidance

FTC comments on FDA biosimilar naming guidance

WASHINGTON — The staff of the Federal Trade Commission has submitted comment for the Food and Drug Administration’s draft guidance on nonproprietary names for biological products. The FTC said Wednesday that its staff comment expressed concern that the FDA draft guidance on biosimilar naming may hinder competition and, as a result, recommended that the agency